• Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact
Contact Icon Contact Icon Contact Icon
  • Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact
  • Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact

The Disease

WHO Group 2 : Pulmonary Hypertension with Left Heart Disease

Group 2 pulmonary hypertension is the most prevalent cause of pulmonary hypertension worldwide, representing >50% of cases. Within that group Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)  represents the most common form, with an estimated US prevalence of more than 1.5 million patients.

Clinically, these patients present with symptoms identical to Group 1 PAH patients, namely shortness of breath, leg edema, and poor exercise capacity. The distinction between these two groups requires medical testing, including a right heart catheterization.  The disease involves abnormalities of the left ventricle which has reduced compliance, an elevation in the left atrial pressure (aka pulmonary capillary wedge pressure (PCWP), an elevation in pulmonary arterial pressure, and reduced function of the right ventricle. Thus, it is a complex disease involving the heart and pulmonary circulation together.

Our Products
Education Center Publications
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Contact
    • Email

Tenax Therapeutics

Specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension.

Contact Icon Contact Icon Contact Icon

© Copyright 2023 Tenax Therapeutics. All Rights Reserved.
Site created by Top Shelf Design

  • Privacy Policy
  • Terms of Service